Close

Oculus Innovative Sciences (OCLS) Announces U.S. Launch of Lasercyn

Go back to Oculus Innovative Sciences (OCLS) Announces U.S. Launch of Lasercyn

Oculus Innovative Sciences Launches Lasercynâ„¢ into U.S. Dermatology Market for Use Following Laser Procedures, Microdermabrasions and Chemical Peels

August 30, 2016 4:05 AM EDT

PETALUMA, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the commercial launch into the U.S. dermatology market of the companys newest dermatology product, Lasercyn. Under the supervision of a healthcare professional, Lasercyn is intended for the management of post-non-ablative laser therapy procedures, post-microdermabrasion therapy and following superficial chemical peels. Lasercyn may also be used to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns.

Dr. Michael Gold,... More